Microsoft co-founder pledges $300m to brain research

By Admin
The co-founder of Microsoft, Paul Allen, has promised to donate £300 million of his personal fortune into brain research. He is planning to inves...

The co-founder of Microsoft, Paul Allen, has promised to donate £300 million of his personal fortune into brain research.

He is planning to invest the money into the organisation he set up, the Allen Institute for Brain Science, over the next three years.

Allen has said the money will go towards understanding how the brain works, an investigation which will have three main research initiatives.   

The project is expected to take 10 years to complete and the $300 million donation means Allen’s personal donations to the Institute now total $500 million.  

To read the latest edition of Healthcare Global, click here

The three following questions will form the basis of the research:

  • How does the brain store, encode and process information?
  • What are the cellular building blocks that underlie all brain function, and are often targets of disease?
  • How do those cells develop, and then create the circuits that drive behavior, thought and brain dysfunction?

To carry out such an in-depth investigation, there are plans to double the current employee compliment to 350 over the next four years, and hiring has already begun.  

Alan has charged the Institute with tackling some of the most fundamental and complex questions in brain science today.

The answers to such questions are essential for achieving a complete understanding of how the brain works, what goes wrong in brain-related diseases and disorders, and how best to treat them.

Commenting on the donation, Allen said: “The accomplishments of the Institute have been truly remarkable.

“With its disciplined, mission-focused approach, the Institute has successfully tackled big-science projects, delivering tangible results that are helping to advance brain research around the world every day.”

“I am excited to expand the scale and scope of the Institute's efforts, and I look forward to seeing what we will accomplish in the future,” he added.

Meanwhile Allan Jones, CEO of the Allen Institute for Brain Science, said: “Paul Allen's generosity and bold vision have allowed us to build a unique organisation and advance brain research in ways that wouldn't be possible otherwise.

“This new funding enables us to apply our structured, industrial-scale approach to science to tackle increasingly complex questions about how the brain works—questions that must be answered if we are to understand and treat autism, Alzheimer's disease, depression, traumatic brain injury and the myriad other brain-related diseases and disorders that affect all of us either directly or indirectly.”

The Healthcare Global magazine is now available on the iPad. Click here to download it.

Share

Featured Articles

Grifols & Orange Business Launch Egypt Plasma Project

Grifols & Orange Business Complete landmark phase of Data Centre for Plasma Derivatives Facility, designed to boost healthcare in Egypt

Healthcare business roundup: Eli Lilly, Novo Nordisk, Aspen

Eli Lilly's experimental cardiovascular drug ‘promising’; Aspen Pharmacare to manufacture mpox vaccines; Novo Nordisk says Ozempic shortage ‘worsening’

Global Health Funding 'Facing Post-Pandemic Challenges'

IHME report highlights shifting priorities and economic pressures affecting global health financing, despite increase in funding since pre-COVID levels

The Merck Group: Pharma's History & Innovation in India

Medical Devices & Pharma

How CVS Health is Rising to the Omnichannel Challenge

Procurement & Supply Chain

Kinaxis: Pharma Seeing Euro-wide Supply Chain Challenges

Procurement & Supply Chain